Poseida Therapeutics ($PSTX) stock is skyrocketing today on news that the company has reached an acquisition agreement with Roche Holdings ($RHHBY). Known for its work in the fields of allogeneic
Poseida Therapeutics ($PSTX) stock is skyrocketing today on news that the company has reached an acquisition agreement with Roche Holdings ($RHHBY). Known for its work in the fields of allogeneic
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1. STOCK NEWS: President-elect Donald Trump said he plans to sign an
ארתור הי, אנליסט ב-. .C. Wainwright, הוריד את Poseida Therapeutics (PSTX) לדירוג החזקה מדירוג קנייה. מחיר היעד הוא כעת 9$, הורד מ-20$. ההורדה הזו מגיעה בעקבות הסכם של Roche (RHHBY)
H.C. Wainwright analyst Arthur He downgraded Poseida Therapeutics (PSTX) to Neutral from Buy with a price target of $9, down from $20, after Roche (RHHBY) agreed to acquire the company
William Blair downgraded Poseida Therapeutics (PSTX) to Market Perform from Outperform after Roche (RHHBY) agreed to acquire Poseida for $13 per share in cash, comprised of $9 per share in